Expanding the horizon of oligonucleotide therapeutics

 

More potent clinical leads with fewer side effects at a lower dosage/cost, delivered to non-liver sites

Our Mission

At pacDNA, we aim to transform the field of oligonucleotide therapeutics with safer and more potent drugs that distribute to a wide range of non-liver organs and tissues such as the heart, blood, lung, skeletal muscle, skin, and bone. Our mission is to greatly expand the disease areas where an oligonucleotide-based therapy can be developed, to include major disease categories such as cancer, immunology, metabolic disease, and infectious diseases.

 

Our proprietary delivery technology, termed the Brushield™, boosts the biodistribution in otherwise hard-to-deliver sites, which makes it possible to develop multiple therapies for diseases that are currently out of reach. The technology also promotes tissue retention to up to several months, producing lasting potency. With our technology, there is potential to yield much better treatments, with very low toxicity or side effects from the carrier, increased potency, and smaller, less frequent dosages.

Brushield™

Conventional gene regulation agents face a difficult dilemma. The combined challenges of poor tissue accumulation and rapid clearance of agents by the liver and kidney require larger doses of agents. Increased doses lead to toxicity and inflammatory or immune responses. Collectively, these challenges limit the therapeutic window between a therapy that is efficacious and one that is toxic, increase the costs to patients, and very often limit the places in the body where effective therapies can be developed.

 

What is Brushield™? It is an oligonucleotide enhancer technology that will allow pacDNA to significantly accelerate lead-to-IND stage drug development for our clients and partners. The technology mitigates toxicities and almost all other side effects stemming from unwanted nucleic acid-protein interactions, while making the active component more efficacious. The Brushield™ technology is highly differentiated  and can yield drug candidates with far superior biopharmaceutical properties including reduced side effects, non-immunogencity, enhanced  pharmacokinetics, and non-liver/kidney biodistribution. Our research has generated substantial data pointing to Brushield™ being a highly translatable approach for realizing non-hepatic gene regulation, which remains a key challenge in the development of viable therapeutics.

No anti-carrier immunity Delivery to non-liver sites Increased bioactivity in vivo Suppression of side effects
News

(2022-09-01) pacDNA is launching with $2.4M Fast-Track NCI STTR grant to develop its oncology candidate

Read More

(2022-09-26) pacDNA is selected to join the Fall 2022 cohort of MassBioDrive Accelerator

Read More

(2022-10-18) pacDNA is the winner of the Golden Ticket Competition sponsored by BioMarin Pharmaceutical Inc.

Read More

(2022-10-26) pacDNA will be joining the  LabCentral community at 700 Main St.

Read More

(2022-11-01) pacDNA is a Featured Honoree at the BPLA Invented Here! event for its foundational patent

Read More

(2023-01-12) pacDNA is an awardee of the Northeastern University Spark Fund

Read More

(2023-05-17) pacDNA is selected to present at the LabCentral VC Showcase event

Read More

(2023-06-08) pacDNA is excited to showcase our science at the 2023 BIO Startup Stadium

Read More

(2023-09-14) pacDNA Founder, Prof. Ke Zhang, receives the Kabiller Rising Star Award

Read More

(2023-05-08) pacDNA participates in the NIH Innovation Corps (i-Corps) programs

Read More

(2023-10-16) pacDNA is showcasing our technology at the PODD conference as a Soapbox Sponsor

Read More

(2024-02-01) pacDNA is proud to receive a second Spark Fund award

Read More

(2024-02-01) pacDNA is excited to collaborate with the Nanotechnology Characterization Laboratory

Read More
Our Pipeline

pacDNA strives to use our Brushield™ oligonucleotide enhancer technology to bring life-changing medicines to patients. Our technologies enable rapid candidate validation with significantly greater accumulation in target organs, enhanced potency, better safety, and improved pharmacological profile. While we are seeking partnership and out-licensing opportunities, we are also internally  developing a robust pipeline of clinical-stage assets that leverages the unique benefits of the Brushield™ platform with favorable clinical development pathways and a significant unmet clinical need.

 

 

CONTACT INFO

 

support@pacDNAtx.com

 

FCOI Policy

 

© 2023 pacDNA LLC. All rights reserved

Our Mission
Brushield™
No anti-carrier immunity Delivery to non-liver sites Increased bioactivity in vivo Suppression of side effects
News
Our Pipeline
pacDNA Tx